MEPAN Syndrome in an Iranian Child: A Novel Mutation

Authors

  • Fatemeh Arab Department of Advanced Technologies, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Mahsa Boogari Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Najmeh Ahangari Rare Pediatric Neurological Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  • Shima Shekari Department of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Meisam Babaei Department of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran.

DOI:

https://doi.org/10.18502/crcp.v11i2.22384

Keywords:

MEPAN syndrome; Mitochondrial Enoyl-CoA reductase; Pediatrics; MECR gene; Neurodegeneration

Abstract

Mitochondrial Enoyl CoA Reductase Protein-Associated Neurodegeneration (MEPAN) syndrome is an ultra-rare autosomal recessive disorder of mitochondrial fatty acid synthesis, characterized by childhood-onset progressive movement disorder, optic atrophy, and basal ganglia abnormalities. It results from a deficiency of mitochondrial trans-2-enoyl-CoA reductase, an enzyme essential for oxidative phosphorylation and for regulating oxidative stress. We report the first Iranian case of MEPAN syndrome in a 2-year-old boy presenting with developmental delay and several atypical features. Whole-exome sequencing (WES) identified a novel likely pathogenic MECR variant. This case underscores the importance of genetic evaluation in children with unexplained developmental delays and expands the clinical spectrum associated with MECR mutations.

Published

2026-08-24

Issue

Section

Articles